Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo
November 20, 2019Research and Development, Sales and Marketing Cancer, keytruda, pharma
MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of …
Allergan’s acute migraine therapy ubrogepant shows strength at Phase 3
November 20, 2019Research and Development Allergan, pharma, ubrogepant
Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s …
European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma
November 20, 2019Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma
Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …
Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals
November 19, 2019Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma
MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …
Amgen poised to cut 172 positions across US, including California HQ
November 19, 2019Manufacturing and Production Amgen, US, pharma
As revealed in correspondence with the California Employment Development Department, Amgen plans to axe 172 staff positions across the US, …
Bayer and MSD’s chronic heart failure drug meets main goal at Phase 3
November 19, 2019Manufacturing and Production, Research and Development Bayer, MSD, pharma, vericiguat
MSD and Bayer have made it known that their jointly-developed soluble guanylate cyclase (sGC) stimulator vericiguat met its primary endpoint …
Data revealed on novel CRISPR/Cas9 gene-editing therapy for first two severe haemoglobinopathy patients
November 19, 2019Manufacturing and Production, Research and Development Vertex, crispr, pharma
Vertex and CRISPR Therapeutics have unveiled the first interim Phase 1/2 data demonstrating the safety and efficacy of the investigational …
Alkermes snaps up Rodin Therapeutics for a potential $950 million
November 19, 2019Manufacturing and Production, Sales and Marketing Alkermes, Rodin Therapeutics, pharma
Dublin’s Alkermes is set to acquire US firm Rodin Therapeutics in a deal worth a potential $950 million, it has …
Bringing the clinical trial home
November 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, research
Clinical trials are the backbone of healthcare and drug research, but many key patient populations have in the past been …
Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023
November 18, 2019Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma
Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb), its biosimilar version of AbbVie’s Humira, the world’s best-selling drug, …
EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis
November 18, 2019Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
resTORbio shuts down Phase 3 trial in clinically symptomatic respiratory illness
November 18, 2019Research and Development, Sales and Marketing pharma, resTORbio
US firm resTORbio has revealed its intention to terminate a Phase 3 trial of its oral, selective TORC1 inhibitor RTB101 …
Jazz Pharma sleep disorder drug secures CHMP backing for treatment of excessive daytime sleepiness in Europe
November 18, 2019Research and Development, Sales and Marketing EMA, jazz pharma, narcolepsy, pharma, solriamfetol
Jazz Pharma’s solriamfetol has secured a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
Novartis’ Adakveo becomes first FDA-approved P-selectin inhibitor for sickle cell disease
November 18, 2019Sales and Marketing Adakve, Novartis, pharma, sickle cell disease
The FDA has chosen to award Novartis’ Adakveo (crizanlizumab) with marketing authorisation, it has emerged, as a treatment to reduce …
Over half of all anti-vaccine ads on Facebook stem from just two advertisers
November 15, 2019Medical Communications, Research and Development Facebook, anti-vaccine, pharma
A new study has revealed that the largest share of anti-vaccine advertisements on Facebook originate from just two organisations, both …
Shionogi gains US approval in complicated urinary tract infections with Fetroja
November 15, 2019Medical Communications, Sales and Marketing FDA, Fetroja, Shiogoni
Shionogi’s antibacterial therapy Fetroja (cefiderocol) has secured approval in the US for the treatment of complicated urinary tract infections (cUTI), …
Label expansion of Amarin’s Vascepa has unanimous backing of FDA advisory panel
November 15, 2019Medical Communications, Sales and Marketing Amarin, FDA, vascepa
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted in favour of expanding the existing approval of Irish …
Top Ten most popular articles on Pharmafile.com this week
November 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
As we close in on the weekend, it’s been a week characterised by data reveals and crucial marketing approvals, including …
AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes
November 15, 2019Medical Communications, Sales and Marketing AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes
Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to …
New report reveals shocking knowledge gaps around type 2 diabetes risk factors
November 14, 2019Medical Communications, Research and Development Merck KGaA, diabetes, pharma, type 2 diabetes
A new report released on World Diabetes Day has shone a light on a startling lack of knowledge surrounding type …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
